Novartis Shares Plunge After Muscle Drug Fails Phase III Trial 
AstraZeneca Q2 Earnings Beat Forecasts as Oncology Growth Supports 2026 Outlook 
Trump Signs Order to Cut Routine Childhood Vaccines 
Hanmi Pharm Soars 30% on $2.3 Billion Genentech Obesity Drug Deal 
FDA Investigates New Cyclospora Outbreak as U.S. Cases Continue to Rise 
Trump Signs Executive Order to Boost AI Research in Childhood Cancer 
SpaceX’s Starship Completes 11th Test Flight, Paving Way for Moon and Mars Missions 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
Novo Nordisk Eyes Turnaround as Oral Wegovy Challenges Eli Lilly in Weight-Loss Drug Race 
Is space worth the cost? Accounting experts say its value can’t be found in spreadsheets 
Trump Administration Bars U.S. Travelers From Congo Flights Amid Ebola Outbreak 
China vs. NASA: The New Moon Race and What's at Stake by 2030 
Cogent Biosciences Soars 120% on Breakthrough Phase 3 Results for Bezuclastinib in GIST Treatment 
NASA's Artemis II Mission: First Crewed Lunar Journey Since Apollo 
Blue Origin New Glenn Rocket Explodes During Launch Pad Test, Delaying Space Ambitions 
Add as a preferred source on Google
Cancer is one of the leading causes of death in terms of medical issues in the world, affecting over 14 million patients on earth. The number of cancer patients is expected to grow by 2030, reaching over 21.7 million in the process. During that time, an estimated 13 million will have died due to their sickness or complications related to them. In response to the growing medical threat, an alliance comprised of major cancer organizations was formed to essentially create a cancer vaccine.
A significant number of cancer types are treatable, but due to lifestyle choices, work, stress factors, and even environmental influences, the health issue can still persist. In order to find a better way of addressing cancer, the Parker Institute for Cancer Immunotherapy partnered with the Cancer Research Institute and other organizations, Futurism reports.
The Parker Institute for Cancer Immunotherapy is the project of Sean Parker, the tech billionaire. Right now, the alliance counts 30 major organizations as members, including known universities and non-profit groups.
The focus of the alliance’s efforts will be research into neoantigens, which are considered genetic markers for specific cancer tumors. This makes them perfect for quickly detecting cancer within specific individuals, thus making early diagnosis much easier.
More than that, by crunching numbers via algorithms that analyze both DNA and RNA sequences, the presence of neoantigens is easier to detect. Once that happens, it would then be simpler for scientists to come up with a way to make it more visible to the immune system, thus destroying it before tumors appear.
Parker is particularly committed to ensuring that the alliance and its efforts bear fruit at some point, already having donated over $250 million to cancer research, TechCrunch reports. According to him, creating the alliance and directing their efforts to detect tumor markers is exactly what he wanted to achieve when he started his institute.
